[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pigmentary-dispersion-glaucoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pigmentary-dispersion-glaucoma":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100614576","iop-reduction-in-pigmentary-glaucoma-using-dslt-100614576",false,"NCT07281391","IOP Reduction in Pigmentary Glaucoma Using DSLT","Direct Selective Laser Trabeculoplasty Providing Effective Intraocular Pressure Reduction in Pigmentary Glaucoma Patients","Inclusion Criteria:\n\n* Adult patients with pigmentary dispersion syndrome with elevated IOP or mild to moderate (based on AAO Preferred Practice Program criteria) pigmentary glaucoma with glaucomatous optic neuropathy and corresponding visual field\u002FRNFL loss.\n* Treatment naive, or washed out IOP ranging from ≥18-34 mmHg\n* Central corneal thickness (CCT) 480-600 µm\n* Able to complete medication washout and follow-up\n\nExclusion Criteria:\n\n* Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye\n* Prior laser trabeculoplasty \\\u003C3 years\n* Prior intraocular surgery and refractive surgery, except for cataract surgery unless greater than 2 years\n* Patients anticipating cataract surgery within the follow-up period\n* History of ocular inflammation and infection\n* All other secondary glaucoma including exfoliative\n* Patients unable to have DSLT treatment","ALL",{"count":18,"type":19},45,"ESTIMATED","OBSERVATIONAL","This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.",[23,24],"Pigmentary Dispersion Syndrome","Pigmentary Dispersion Glaucoma","RECRUITING","2026-04-08",{"date":28,"type":29},"2026-04-09","ACTUAL",{"date":31,"type":29},"2026-03-19",{"date":33,"type":19},"2027-04-01",{"name":35,"class":36},"Mann Eye Institute","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":37},"100472997","xen-glaucoma-gel-stent-versus-trabeculectomy-100472997","NCT05439161","XEN Glaucoma Gel Stent Versus Trabeculectomy","Multicentric Evaluation of Best Corrected Visual Acuity of the XEN Implant Versus Classic Trabeculectomy in Open Angle Glaucoma Subjects","Inclusion Criteria:\n\n1. Diagnosis of open angle glaucoma (Primary open angle glaucoma, Pseudoexfoliation glaucoma, Pigmentary dispersion glaucoma)\n2. Clinically eligible for both surgeries (Trabeculectomy and XEN) on the discretion of the surgeon (area of healthy, free and mobile conjunctiva in the superior nasal target quadrant)\n3. VA logMAR ≤ 1 (VA dec ≥ 0.1)\n4. Trabecular meshwork must be visible (with Shaffer angle grade \\> 1 in the target quadrant)\n5. Age 18 years or older\n6. Patient understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provides written informed consent\n\nExclusion Criteria:\n\n1. Clinical significant cataract\n2. Subject has had prior cataract surgery in study eye ≤ 1 months (count to operation)\n3. Subject has had prior (incisional) glaucoma surgery (XEN, trabeculectomy, viscocanalostomy, canaloplasty, shunts of any type, collagen implants, etc.). Prior iridotomy is acceptable.\n4. Phacic Angle Closure Glaucoma\n5. Subject has neovascular, uveitic or angle recession glaucoma or any glaucoma associated with vascular disorders\n6. Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis)\n7. Anterior chamber intraocular lens\n8. Vitreous present in the anterior chamber\n9. Presence of intraocular silicone oil\n10. History of corneal surgery, corneal opacities, or corneal disease\n11. Impaired episcleral venous drainage (e.g. Sturge-Weber or nanophthalmos)\n12. History of dermatologic keloid formation\n13. Active diabetic retinopathy, proliferative retinopathy, choroidal neovascularization, branch retinal vein occlusion, central retinal vein occlusion, or other ophthalmic disease or disorder that could confound study results\n14. Known or suspected allergy or sensitivity to drugs required for the surgical procedure or any of the device components (e.g., porcine products or glutaraldehyde),\n15. Pregnant or nursing women","18 Years",{"count":47,"type":19},196,"INTERVENTIONAL",[50],"NA","Multicentric evaluation of best corrected visual acuity of the XEN implant versus classic trabeculectomy in open angle glaucoma subjects",[53,54,24],"Primary Open Angle Glaucoma","Pseudoexfoliation Glaucoma","2025-05-28",{"date":57,"type":29},"2025-06-03",{"date":59,"type":29},"2023-12-20",{"date":61,"type":19},"2026-09-30",{"name":63,"class":36},"Prof. Dr. Herbert Reitsamer"]